514 related articles for article (PubMed ID: 17317584)
21. Chronopharmacology of high-dose busulfan in children.
Vassal G; Challine D; Koscielny S; Hartmann O; Deroussent A; Boland I; Valteau-Couanet D; Lemerle J; Lévi F; Gouyette A
Cancer Res; 1993 Apr; 53(7):1534-7. PubMed ID: 8453619
[TBL] [Abstract][Full Text] [Related]
22. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
[TBL] [Abstract][Full Text] [Related]
23. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.
Dalle JH; Wall D; Theoret Y; Duval M; Shaw L; Larocque D; Taylor C; Gardiner J; Vachon MF; Champagne MA
Bone Marrow Transplant; 2003 Oct; 32(7):647-51. PubMed ID: 13130310
[TBL] [Abstract][Full Text] [Related]
24. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
[TBL] [Abstract][Full Text] [Related]
25. Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors.
Bouligand J; Le Maitre A; Valteau-Couanet D; Grill J; Drouard-Troalen L; Paci A; Hartmann O; Benhamou E; Vassal G
Clin Pharmacol Ther; 2007 Oct; 82(4):402-9. PubMed ID: 17392724
[TBL] [Abstract][Full Text] [Related]
26. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
Lee JW; Kang HJ; Lee SH; Yu KS; Kim NH; Yuk YJ; Jang MK; Han EJ; Kim H; Song SH; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2012 Jun; 18(6):944-50. PubMed ID: 22155501
[TBL] [Abstract][Full Text] [Related]
27. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
[TBL] [Abstract][Full Text] [Related]
28. Retrospective appraisal of busulfan dose adjustment in children.
Dupuis LL; Najdova M; Saunders EF
Bone Marrow Transplant; 2000 Dec; 26(11):1143-7. PubMed ID: 11149723
[TBL] [Abstract][Full Text] [Related]
29. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation.
Ryu SG; Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Hur EH; Lee SH; Bae KS; Noh GJ; Lee MS; Yun SC; Han SB; Lee KH
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1095-105. PubMed ID: 17697972
[TBL] [Abstract][Full Text] [Related]
30. Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage.
Clopés A; Sureda A; Sierra J; Queraltó JM; Broto A; Farré R; Moreno E; Brunet S; Martino R; Mangues MA
Eur J Haematol; 2006 Jul; 77(1):1-6. PubMed ID: 16573745
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and tolerability of intravenous busulfan in hematopoietic stem cell transplantation.
Cho YH; Lim HA; Lee MH; Kim I; Lee JS; Park Sy; Kim BK; Yoon SS
Clin Transplant; 2007; 21(3):417-22. PubMed ID: 17488395
[TBL] [Abstract][Full Text] [Related]
32. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.
McCune JS; Gooley T; Gibbs JP; Sanders JE; Petersdorf EW; Appelbaum FR; Anasetti C; Risler L; Sultan D; Slattery JT
Bone Marrow Transplant; 2002 Aug; 30(3):167-73. PubMed ID: 12189535
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
McPherson ME; Hutcherson D; Olson E; Haight AE; Horan J; Chiang KY
Bone Marrow Transplant; 2011 Jan; 46(1):27-33. PubMed ID: 20305698
[TBL] [Abstract][Full Text] [Related]
34. Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation.
Kim AH; Tse JC; Ikeda A; Moore TB
Pediatr Transplant; 2009 Dec; 13(8):971-6. PubMed ID: 19032412
[TBL] [Abstract][Full Text] [Related]
35. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
Aggarwal C; Gupta S; Vaughan WP; Saylors GB; Salzman DE; Katz RO; Nance AG; Tilden AB; Carabasi MH
Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066
[TBL] [Abstract][Full Text] [Related]
36. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
[TBL] [Abstract][Full Text] [Related]
37. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
Ansari M; Lauzon-Joset JF; Vachon MF; Duval M; Théoret Y; Champagne MA; Krajinovic M
Bone Marrow Transplant; 2010 Feb; 45(2):261-7. PubMed ID: 19584821
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.
Madden T; de Lima M; Thapar N; Nguyen J; Roberson S; Couriel D; Pierre B; Shpall EJ; Jones RB; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2007 Jan; 13(1):56-64. PubMed ID: 17222753
[TBL] [Abstract][Full Text] [Related]
39. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.
Michel G; Valteau-Couanet D; Gentet JC; Esperou H; Socié G; Méchinaud F; Doz F; Neven B; Bertrand Y; Galambrun C; Demeocq F; Yakouben K; Bordigoni P; Frappaz D; Nguyen L; Vassal G
Pediatr Blood Cancer; 2012 Jan; 58(1):90-7. PubMed ID: 21254374
[TBL] [Abstract][Full Text] [Related]
40. Individualizing oral busulfan dose after using a test dose in patients undergoing hematopoietic stem cell transplantation: pharmacokinetic characterization.
Effting C; de Moraes Arantes A; Queiroz Labre LV; Carneiro WJ; de Oliveira Neto JR; Bariani C; Rodrigues CR; Rodrigues AR; Cunha LC
Ther Drug Monit; 2015 Feb; 37(1):66-70. PubMed ID: 25588069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
